Genmab Reports Three Phase 3 Wins; Shares Rose 91.5% From Aug. 3 to Nov. 2
Photo: TokenPost
Genmab reported positive results from three Phase 3 cancer trials in October, while its Nasdaq-listed shares rose 91.5% from Aug. 3 to Nov. 2 as the company pursues greater ownership of medicines it develops. The American depositary shares closed at $28.68 on Aug. 3 and $54.92 on Nov. 2. The comparison period began before the October trial announcements and ended five days after the latest result. On Oct. 28, Genmab reported first interim results for petosemtamab in first-line treatment of patients with PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma.
Source: TokenPost
